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arkus Meyer, MD, FACC, Martin M. LeWinter, MD, FACC, Stephen P. Bell, BA,
engyi Chen, MD, Donald E. Selby, PHD, Dinender K. Singla, PHD,
arold L. Dauerman, MD, FACC
urlington, Vermont
bjectives We sought to evaluate the cardiac and renal effects of an N-acetylcysteine (NAC)-en-
anced intracoronary radiographic contrast agent.
ackground Recent studies suggest that high-dose NAC provides better protection from contrast-
nduced nephropathy, and the antioxidant properties of NAC may also provide cardiac protection.
he use of angiographic contrast agents as a drug delivery vehicle for cardiorenal protection effects
as not been investigated.
ethods In a pig model of prolonged cardiac ischemia-reperfusion, NAC-enhanced contrast me-
ium was tested and compared with iopamidol contrast only. Myocardium and renal function were
ssessed after 24 h.
esults There was no signiﬁcant difference in the area-at-risk for myocardial infarction (MI) be-
ween contrast only and NAC-enhanced contrast medium. In contrast, MI size was about 40%
maller in NAC-enhanced contrast medium–treated animals. These ﬁndings were associated with a
igniﬁcant difference in MI morphology. MIs in the NAC-enhanced contrast medium group had a
ottled appearance, whereas in the contrast only group they were homogeneous and had a dis-
rete border zone. These differences could explain a higher incidence of periprocedural ventricular
rrhythmias in the NAC-enhanced contrast medium group. Histopathological analysis of the myocar-
ium revealed a reduction in programmed cell death by NAC-enhanced contrast medium that may
xplain the increase in ischemia tolerance. Last, NAC-enhanced contrast medium administration
lunted the rise in serum creatinine levels by about 60% and protected from renotubular apotosis.
onclusions NAC-enhanced contrast medium reduces MI size and protects renal function in a pig
odel of ischemia and reperfusion. (J Am Coll Cardiol Intv 2009;2:215–21) © 2009 by the American
ollege of Cardiology Foundation
rom the Division of Cardiology, University of Vermont College of Medicine, Burlington, Vermont. This study is funded
y general developmental funds (Dr. Dauerman). A patent application is submitted “Methods and Compositions for
rgan Protection.”anuscript received September 22, 2008; revised manuscript received November 4, 2008, accepted November 7, 2008.
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216ontrast-induced nephropathy (CIN) remains a significant
omplication after cardiovascular catheterization proce-
ures. While the overall risk of CIN complicating cardio-
ascular procedures is now less than 5%, this risk can exceed
0% in the setting of pre-existent renal failure, diabetes
ellitus, reduced left ventricular ejection fraction, and large
ontrast loads (1–3). Since a reduction in CIN would
mprove procedural outcomes, recent efforts have focused on
nding adjunctive agents that reduce the nephrotoxic effects
f the available contrast agents (4).
See page 222
N-acetylcysteine (NAC) is an antioxidant agent with
otential myocardial and renal protective effects (5–7).
lthough the use of NAC for prevention of CIN is still
ontroversial, many clinical trials indicate a beneficial effect
8). In a recent trial that combined oral and intravenous
NAC administration, an en-
hanced benefit of high-dose
NAC was demonstrated among
patients undergoing percutane-
ous coronary interventions (9).
The sample size in this trial was
large enough to demonstrate a
dose-dependent mortality re-
duction.
We hypothesized that adding
NAC to an intracoronary con-
trast agent would match the
NAC dose to the contrast vol-
ume and provide adjusted renal
protection with a potential for
additional myocardial protec-
tion. A proof-of-concept study
was designed that would maxi-
ize the cardiac protective effects of NAC. In a pig model
f prolonged myocardial ischemia and reperfusion, a fixed
olume of contrast NAC mixture was administered before
nd after the coronary occlusion. The study end points were
nfarct size, area of myocardium at risk, infarct morphology,
ardiac/renal apoptosis, and renal function.
ethods
afety of intracoronary NAC. Although intracoronary NAC
nfusions are reported to be safe in humans, the effects of
ntracoronary bolus injections are not known (10). Accord-
ngly, the effects of intracoronary NAC mixed with contrast
edium on blood pressure and cardiac rhythm were tested
n 2 pigs. All aspects of animal care were in accordance with
he National Institutes of Health guidelines and the stan-
ards of the Animal Care and Use Committee of the
bbreviations
nd Acronyms
IN  contrast-induced
ephropathy
API 
’,6-diamidino-2-phenylindole
CCV  direct
ountercurrent cardioversion
AD  left anterior
escending artery
AC  N-acetylcysteine
TC  (2,3,5)-
riphenyltetrazolium chloride
UNEL  terminal uridine
eoxynucleotidyl transferase
UTP nick end labelingniversity of Vermont. tAfter pre-medication with ketamine (20 mg/kg), the pigs
ere anesthetized with isoflurane, intubated and ventilated.
femoral artery sheath was placed, and a JR 4 or HS guide
atheter was placed at the left main coronary artery. Twelve-
ead electrocardiogram (ECG) and catheter pressures were
ontinuously recorded.
A NAC dose of 11.3 mg/ml of iopamidol contrast
Isovue 370, Bracco Pharmaceuticals, Princeton, New Jer-
ey) was chosen because it would deliver between 1 to 2 g of
AC for an average interventional case. As a clinical
eference point, this dose is similar to the highest dose
dministered by Marenzi et al. (9) and about 10-fold below
he recommended intravenous dose for the treatment of
cetaminophen overdose (11). The dose was obtained by
dding 12 ml of NAC solution (Acetadote, Cumberland
harmaceuticals, Nashville, Tennessee) to a 200-ml lopam-
dol glass container.
At least 5 injections of the contrast plus NAC per animal
ere performed. After the experiment, the pigs were mon-
tored for an additional hour. Blood pressure and QT
nterval were analyzed at the end of 3 succeeding respiratory
ycles (6, 12, and 18 s after injection) and are reported as a
ean percent change from baseline.
fﬁcacy in ischemia-reperfusion. EXPERIMENTAL PROTO-
OL. The pigs (28  5 kg) were assigned to either iopam-
dol contrast alone (n  5) or contrast containing NAC at
concentration of 11.3 mg/ml (n  7). Adding the NAC
olution to the contrast agent does not significantly reduce
he contrast quality of the angiograms based on our mea-
urements using our previously described technique of
uantitative fluoroscopy (12). The pigs were prepared as
escribed in the safety study. All pigs received a heparin
olus (2,000 U). A guidewire (PT2, Boston Scientific,
atick, Massachusetts) and balloon (Monorail Maverick,
.5  15 mm, Boston Scientific) was advanced into the left
nterior descending artery (LAD) followed by balloon
nflation just distal to the second diagonal branch. Total
cclusion time was 60 min. A fixed volume of 200 ml of
ontrast medium was administered to each animal. Approx-
mately one-half of the contrast volume was used to place
he equipment resulting in NAC administration before the
schemic event to maximize its potential beneficial effect.
he remaining contrast was injected during the reperfusion
eriod. After approximately 30 min, all equipment was
ithdrawn. A femoral artery closure device (Angio-Seal, St.
ude Medical, St. Paul, Minnesota) was deployed. After the
xtubation, the animals were transferred to the housing
acility. No animal died during housing.
After 24 h, the animals were resedated and intubated. A
ternotomy was performed. Ligatures were placed at the
roximal balloon occlusion site, the aortic arch branches,
nd the descending aorta. A cannula was advanced into the
ortic root from a right carotid arterial access and connected
o 1.5% Evans Blue dye, Sigma-Aldrich, St. Louis, Mis-
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217ouri. The vessels were then occluded in the following order:
AD, aortic arch branches, and descending aorta. The dye
as then injected at a pressure of 120 mm Hg until the
yocardium was stained. The unstained myocardium distal
o the LAD ligature was defined as the area-at-risk. Two
AC-treated hearts could not be used for the morphomet-
ic analysis due to dye wash-out and a failed cardioversion.
EMODYNAMIC AND ELECTROCARDIOGRAPHIC RECORDING.
fter the deflation of the balloon, blood pressure, heart rate,
nd ECG were recorded for another 30 min. Ventricular
achycardia (4 beats) or ventricular fibrillation during
oronary occlusion or reperfusion were documented. Direct
ountercurrent cardioversion (DCCV) was provided for
emodynamic instability. No antiarrhythmic medications
ere used.
REA-AT-RISK AND INFARCT MEASUREMENTS. The hearts
ere harvested, and the ventricles were sliced into 1-cm cuts
n a bread loaf fashion, with the first slice at the apex. The
asal surfaces of the slices were imaged. Samples of myo-
ardium from areas of necrosis, area-at-risk, and normal left
entricular myocardium were obtained from the apical side
f the second and third slice and stored for additional
nalyses. Thereafter, all slices were incubated in a solution
ontaining 1.5% (2,3,5)-triphenyltetrazolium chloride (TTC)
or 25 min. The basal surfaces were then reimaged, and area
nalysis (planimetry) was performed (Scion Image 4.0.2,
cion Corp., Frederick, Massachusetts). The size of the
rea-at-risk and infarct size for each slice was determined by
ultiplying the mass of the slice by the fraction of area-at-
isk or by the fraction of area of infarction. Total infarct size
nd the area-at-risk size were expressed as a percentage of
iventricular mass.
NFARCT MORPHOLOGY. In order to quantify the apparent
ifferences in infarct morphology, a circumference/area
ndex of the infarcted myocardium using TTC-stained
ections was calculated. A low numerical value indicates a
omogenous and discrete border zone, whereas a higher
umerical value indicates a more complex, mottled border.
POPTOSIS. Terminal uridine deoxynucleotidyl transferase
UTP nick end labeling (TUNEL) stains (in-situ apoptosis
etection, Roche, Indianapolis, Indiana) of nonischemic,
rea-at-risk, and infarcted tissue samples were performed. A
otal of 4 samples from 2 control animals and 6 samples
rom 3 NAC-treated animals were analyzed. Tissue sections
ere deparaffinized and permeabilized with proteinase K.
ections were mounted with Vectashield mounting medium
ontaining 4’,6-diamidino-2-phenylindole (DAPI) (Vector
aboratories, Burlingame, California) as a nuclear counter-
tain. The percentage of apoptotic nuclei per section was
alculated by counting the total number of TUNEL-
taining nuclei divided by the total number of DAPI-
ositive nuclei as previously described (13). Microscopic
valuation of TTC-negative myocardial infarction tissue
evealed hemorrhage and areas of contraction band necrosis gssociated with a minimal loss in cross striations. This was
ot observed in the noninfarcted or area-at-risk tissue.
enal TUNEL results were quantified as the number of
UNEL plus DAPI-positive epithelial cell nuclei per prox-
mal tubule cross section from 3 control and 4 NAC-treated
amples.
erum analysis. Serum that was collected before contrast
xposure and 24 h after infarction was analyzed for creati-
ine concentrations.
tatistical analysis. End points were infarct and area-at-risk
ize, infarct morphology, percentage of TUNEL-positive
ells, and change in serum creatinine at baseline and after
4 h of reperfusion. End points between the NAC-
nhanced contrast group and iopamidol contrast only group
ere compared by 1-way analysis of variance. In the dose
scalation study, the effect of each injection on blood
ressure and QT interval was expressed as a percentage
hange from the immediately preceding baseline and ana-
yzed by a Wilcoxon matched-pairs signed ranks test. A
value of 0.05 was accepted as statistically significant. All
esults are reported and depicted as mean ( SD).
The authors had full access to the data and take respon-
ibility for its integrity. All authors have read and agree to
he manuscript as written.
esults
ntracoronary NAC dose escalation: blood pressure and QT
nterval. Injections of contrast containing NAC did not
ause any arrhythmias or changes in heart rate. Immediately
fter the injection of 5 ml of contrast containing 11.3 mg/ml
AC, we observed a brief reduction of systolic blood
ressures averaging 5% at the 6-s time point after the
njection (p  0.05). This was accompanied by a transient
7% reduction in diastolic blood pressure (p  0.05). At
8 s, systolic pressure had returned to pre-injection pres-
ures, whereas diastolic pressure continued to be decreased
y 7% (p  0.05). Complete normalization of blood
ressure was achieved after 45 to 60 s. Control injections
ith iopamidol contrast did not show such effects.
ffect of intracoronary NAC on myocardial infarction. Com-
arison of the non–Evans Blue-stained areas reflecting the
rea-at-risk in NAC-treated animals (n  5) and control
nimals (n  5) did not reveal a significant difference.
xpressed as a percentage of ventricular myocardium, area-
t-risk was 15.1  4.8% in control hearts and 18.4  1.8%
n NAC-treated hearts (p  0.2). Infarct size as percent of
entricular myocardium determined by TTC staining was
3.9  4.5% in control animals and 8.2  2.3% in
AC-treated animals (p  0.05). Infarct size expressed as a
ercentage of the area-at-risk was 92.4  6.3% in controls
earts and 44.7 12.4% in NAC-treated hearts (p 0.01),
uggesting a NAC-mediated protection from infarct pro-
ression (Fig. 1).
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218The morphologic appearance of the infarcted area dif-
ered markedly between the 2 groups. Infarcts in control
nimals were homogeneous with discrete borders while
nfarcts in NAC-treated animals contained areas of viable
yocardium interspersed with infarcted areas resulting in a
ottled appearance. Reflecting this difference, the ratio of
nfarct circumference to infarct area was greater in NAC-
reated animals (Figs. 2A and 2B).
To investigate if the protective effect of NAC is mediated
y protection from apoptosis, we performed TUNEL as-
ays. In myocardium obtained from non-LAD territories
nonischemic), we found a low number of TUNEL-positive
yocyte nuclei without a significant difference between
Figure 1. Myocardial Infarct Size and Area-at-Risk
A depicts the area-at-risk and the area of infarction in 5 control (iopamidol
contrast-only) and 5 N-acetylcysteine (iopamidol contrast plus 11.3 mg/ml
N-acetylcysteine) treated pig hearts expressed as percentage of ventricular
myocardium. The bar graph in B depicts the percentage of the area-at-risk
that was infarcted in both control animals and N-acetylcysteine–treated
animals. LV  left ventricle; RV  right ventricle.AC-treated and control animals. Within the infarct tissuef control animals, 35.8  5.7% of nuclei stained positive
or apoptosis compared with 33.0  3.7% in NAC-treated
nimals (p  0.4). In contrast, in tissue obtained from the
oninfarcted area-at-risk obtained from control animals,
2.1  4.0% of nuclei stained TUNEL positive, whereas
his value was 1.6  1.6% in NAC-treated animals (p 
.001), suggesting NAC-mediated protection from apopto-
is (Fig. 3). To further study if sample location within the
rea-at-risk might have contributed to our findings, we
eviewed our microscopic slides for gradual changes in
poptosis rates within our samples (e.g., reduction in apop-
osis rates towards the outer risk zones). No such gradients
ere apparent.
eriprocedural arrhythmias. Neither animal in the dose
scalation study and none of the control ischemia-
eperfusion animals developed ventricular fibrillation or
equired DCCV. One control animal had a brief episode of
elf-terminating ventricular tachycardia during reperfusion.
n contrast, all NAC-treated animals developed ventricular
achycardia, fibrillation, or both during ischemia-
eperfusion. All of these events occurred either in the second
alf of the balloon occlusion or during the first 15 min of
eperfusion. There was no temporal association between
Figure 2. Myocardial Infarct Heterogeneity
A demonstrates an example of the infarcted area (black) in a left ventricu-
lar slice obtained from a control (iopamidol contrast-only) and N-acetylcys-
teine (iopamidol contrast with 11.3 mg/ml N-acetylcysteine) treated animal.
The infarction in the N-acetylcysteine–treated animal is mottled with inter-
spersed areas of viable myocardium (brown). The numerical values reﬂect
the ratio of the infarct circumference to infarct area an index for infarct
heterogeneity. The bar graph in B depicts the results of the group analysis.
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219AC injection and the onset of the arrhythmia. Episodes of
solated ventricular tachycardia in the NAC group were of a
onger duration compared with the one observed episode in
control animal. Most often ventricular tachycardia degen-
rated rapidly into ventricular fibrillation in the NAC-
reated animals. DCCV only failed once due to a 4-min
ime delay. One animal in the NAC group that could not be
sed for the morphometric myocardial infarction analysis
ue to insufficient Evans Blue staining had an episode of
entricular tachycardia followed by fibrillation after initiat-
ng anesthesia on day 2 of the study. Periprocedural arrhyth-
ias are summarized in Table 1.
ffect of intracoronary NAC on serum creatinine levels and
enal apoptosis. Blood samples for creatinine were obtained
efore the administration of the contrast agent and 24 h
Figure 3. Myocardial Apoptosis
Bar graph depicting the percentages of terminal uridine deoxynucleotidyl
transferase dUTP nick-end labeling positive nuclei reﬂecting apoptosis in
nonischemic, area-at-risk, and in infarcted myocardium from control and
N-acetylcysteine–treated animals.
Table 1. Significant Arrhythmias During Occlusion and Reperfusion
Control
1 none
2 none
3 none
4 VT, self-terminating (2 min reperfusion)
5 none
N-acetylcysteine
1 VT, VF, successful cardioversion (7 min reperfusion)
2 VT, self-terminating, (45 min occlusion)
3 VT, self-terminating (5 min reperfusion)
4 VF, successful cardioversion (10 min reperfusion)
5 VT, VF, unsuccessful cardioversion (38 min occlusion)
6 VT, VF, successful cardioversion (5 min reperfusion)
7 VT, VF, successful cardioversion (33 min occlusion)
Ventricular tachycardia (VT), ventricular fibrillation (VF), and direct countercurrent cardioversion
in pigs undergoing an ischemia-reperfusion protocol. The control animals received iopamidol
contrast only, whereas animals in the N-acetylcysteine group received N-acetylcysteine added topthe iopamidol contrast agent.fter infarction. Baseline creatinine level before contrast
edium administration was 1.32  0.26 mg/dl in the
ontrol group and 1.29  0.15 mg/dl in the NAC-treated
roup. One day after contrast exposure, creatinine levels
ose to 1.82  0.24 mg/dl in the control group (p  0.05)
nd 1.49  0.06 mg/dl in the NAC-treated animals (p 
.05). The comparison of the 24-h creatinine levels in the
AC versus control groups showed a significant reduction
n creatinine levels indicating a protective effect of NAC
p  0.05). These data are summarized in Figure 4.
Additionally TUNEL assays of renal tissue revealed that
poptosis rates of epithelial cells in the proximal tubules
ere reduced by approximately 75% in NAC-treated ani-
als (0.42 vs. 0.11 TUNEL plus DAPI-positive nuclei/
roximal tubule).
iscussion
he present study demonstrates that intracoronary admin-
stration of a radiographic contrast agent mixed with NAC
t a dose similar to those used in a recent clinical trial
rovides cardiorenal protection in a model of ischemia-
eperfusion. Infarct size as a percentage of area-at-risk was
educed by about one-half, and the rise in serum creatinine
fter contrast administration was blunted in NAC-treated
nimals.
irect effects of intracoronary NAC. A small transient QT
rolonging effect of NAC at a dose of 11.3 mg/ml contrast
as observed after intracoronary bolus injections. The
ransient, mild decrease in both systolic and diastolic blood
Figure 4. Contrast-Induced Nephropathy
Graph demonstrating creatinine concentrations before (baseline) and 24 h
after administration of intracoronary iopamidol contrast agent (200 ml).
Where indicated N-acetylcysteine (11.3 mg/ml) was added to the contrast
agent.ressure may indicate a myocardial depressant or a vasodi-
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220ator effect. The latter appears more likely in light of a
revious human trial of intracoronary NAC administration
480 mg over 10 min) that found a NAC-mediated im-
rovement in endothelial function leading to enhanced
asodilation without significant hypotension (10). NAC
ay enhance the bioavailability of nitric oxide by forming
iologically active byproducts or by scavenging the oxygen
ree radicals that are largely responsible for the short
alf-life of nitric oxide (14). The blood pressure effect in
ealthy pigs was small and transient in nature and may have
een induced by the bolus injections since no such effects
ere seen in the human study (10).
ardiac and renal protection. The antioxidative properties
f NAC have been implicated as the mechanism of its
ardioprotective effect (5). In a canine model of myocardial
schemia-reperfusion, both infarct size and reperfusion ar-
hythmias were reduced when intravenous NAC was given
redominantly during reperfusion (15). In 2 clinical studies,
ntravenous NAC was combined with fibrinolytic therapy in
atients with acute ST-segment elevation myocardial in-
arction (5,6). A decrease in infarct size and improved
-wave recovery were reported in association with improved
lobal and regional ejection fraction. Our study design
iffers from the previous animal and human studies in 2
ays: first, we utilized an intracoronary route of adminis-
ration and second, NAC was given both before and after
oronary occlusion to maximize the cardioprotective effect.
s a result, a component of the approximately 40% reduc-
ion in infarct size in the NAC group may be mediated by
n increase in the ischemia tolerance that slows infarction
rogression (16). This could explain the pronounced differ-
nce in infarct morphology in the contrast NAC-treated
nimals. Analysis of the infarcted myocardium revealed
iable areas within the infarct zone in the NAC-treated
nimals, resulting in a heterogeneous and mottled appear-
nce; however, infarcts in control animals were homoge-
ous, with distinct border zones.
The 37% increase in creatinine levels in healthy young
igs with an average body weight of 28 kg was not
nexpected considering that a total of 200 mm of contrast
as administered without periprocedural hydration. This
bservation underscores the impact of contrast volume on
enal function. Our results indicate that NAC administered
ith contrast reduced the rise in creatinine levels by about
0%, which is in line with recent human trials in which high
oses of NAC were used (9,17). Our results show for the
rst time that NAC contrast coadministration without
AC loading is sufficient to mediate a renal protective
ffect. Similar to previous human trials, NAC could be
dministered intravenously. However, coadministration
uarantees that the protective agent (NAC) is delivered
imultaneously leading to a dose increase that is propor-
ional to the injurious agent (contrast volume). aIn extension of the functional improvement in renal
unction, we found an about 75% reduction in the proximal
ubular apoptosis rate in NAC-treated animals. This level of
rotective effect is similar to the results from a human study
emonstrating a NAC-mediated antioxidative protection
rom contrast-induced renotubular injury (18).
rrhythmias. Our results indicate that NAC at a concen-
ration of 11.3 mg/ml can be safely delivered as a bolus to
he coronary circulation during diagnostic angiography in
xactly the same fashion as contrast agents without inducing
emodynamic instability, arrhythmias, or prolonged QT
nterval changes. In contrast, we found an increase in
entricular tachycardia and fibrillation during ischemia-
eperfusion in animals that received NAC. These arrhyth-
ias were not temporally associated with the bolus injec-
ions and responded well to electrical cardioversion if
elivered in a timely manner. No animal died during the
4-h period of housing that followed the procedure.
Our finding in regards to ventricular arrhythmias was
nexpected. It contrasts with a study in which NAC
dministration at the time of reperfusion in a canine
odel was associated with a marked reduction in ven-
ricular arrhythmias (15). No increase in arrhythmias
ere reported in 3 human trials in which intravenously
dministered NAC was given either with lytic therapy or
rimary percutaneous intervention in patient with ST-
egment elevation infarctions (5,6,9). Our finding may be
elated to the changes in the infarct morphology with
reas of viable myocardium interspersed into infarcted
reas. Such mottled infarction patterns are well docu-
ented to provide foci and re-entry pathways for ven-
ricular arrhythmias (19,20). Since this proof-of-concept
tudy was designed to maximize the cardiac efficacy, our
esults in regard to the arrhythmias may have been
ntroduced by pre-loading the animals with NAC thus
ltering the evolution of the myocardial infarction.
tudy limitations. We did not measure the antioxidative
ffects of NAC although this has been done directly in a
rior human trial (5). It is possible that other mechanisms
ay contribute to our findings of cardiorenal protection.
he occurrence of a potentially life-threatening ventricular
rrhythmia presents a very serious issue that if reproduced in
clinical setting would prevent the use of this novel agent in
cute myocardial infarctions. Initial clinical evaluation may
hus be first targeted towards elective PCI cases at high risk
or acute renal failure and lower risk for ventricular arrhyth-
ias. Despite a significant difference in the studied end
oints between the groups the sample size in this proof-of-
rinciple study is small. A larger animal study that more
ccurately simulates clinical practice in respect to the timing
f the NAC contrast mixture is necessary. Altering the
rotocol in a way that the NAC contrast administration
ccurs during the myocardial infarction is not expected to
ffect renal efficacy but could significantly reduce the cardiac
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221enefit, which in turn may reduce the incidence of ventric-
lar arrhythmias.
onclusions
e have demonstrated the feasibility and efficacy of deliv-
ring NAC in conjunction with an intracoronary contrast
gent to provide combined cardiac and renal protection in
he setting of ischemia-reperfusion. This observation may
ave potential application in clinic practice. The use of
ontrast agents enriched with NAC would guarantee that
atients who receive large amounts of contrast medium and
re, therefore, at a higher risk of CIN would be protected by
arger doses of NAC. Furthermore, our results are consis-
ent with prior studies suggesting that NAC provides
ignificant myocardial protection during ischemia-
eperfusion. As noted earlier, the potential risk of ventric-
lar arrhythmias as well as the magnitude of cardiac and
enal protection will need to be carefully assessed in future
nimal studies that more closely simulate clinical practice.
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